September 25, 2024 7:49am
Caution, move carefully as concerns that volatility remains on the surface of financial markets
“Uncle algo and his electronic trading dwarfs” did assist Tuesday’s close, will they continue?
Pre-open Indications: 1 Sell into Strength, 3 Negative and 3 Positive Indications
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
Never leave an investor uninformed
Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
Wednesday: The pre-open Dow futures are UP +0.05% or (+22 points), the S&P futures are DOWN -0.03% or (-1 points) and the Nasdaq futures are DOWN -0.18% or (-36 points)
- Stock futures were mixed and slipping on Wednesday,
- European markets inched lower,
- Asia-Pacific markets were ascending in China and Australia
Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies
Tuesday: The Dow closed UP +83.57 points or +0.20%, the S&P closed UP +14.36 points or +0.25% while the Nasdaq closed UP +100.25 points or +0.56%
- Tuesday’s advance/decline line ended with a positive close at the close of 18 incliner, 15 decliners and 2 flats
Economic Data Docket: Economic data: MBA Mortgage Applications, week ending September 20 (14.2% prior); New home sales, August (693,000 expected, 739,000 prior); New home sales month over month, August (-6.3% expected, 10.6% previously)
Tuesday’s RegMed Investors (RMi) Closing bell: “Big disappointment, consumer confidence data. Although “Uncle algo and his electronic trading dwarfs” were outside the door, coming-in for a visit with a late session present - a positive close.” …. https://www.regmedinvestors.com/articles/13628
Q3/24:
- September – 7 positive and 9 negative close
- August – I neutral, 10 positive and 11 negative closes
- July: 1 market holiday. 1 day off, 6 negative, 1 neutral and 12 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context
I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.
A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
Sell into Strength:
Tuesday, Monday, Friday, Thursday, Wednesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Mesoblast (MESO) closed up +$0.53 +$0.44 with a positive +$0.11 or +1.51% aftermarket.
Negative Indications:
Tuesday, Monday, Friday, Thursday, Wednesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Agenus (AGEN) closed down -$0.13 after Monday’s -$0.54with a positive -$0.07 or -1.32% Tuesday aftermarket
Regenxbio (RGNX) closed down -$0.46 with a negative -$0.09 or -0.80% aftermarket
Sage Therapeutics (SAGE) closed up +$0.08 with a negative -$0.16 or -2.19% aftermarket
Positive Indications:
Tuesday, Monday, Friday, Thursday and Wednesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Editas Medicine (EDIT) closed down -$0.13 with a positive +$0.04 or +1.12% aftermarket
CRISPR Therapeutics (CRSP) closed up +$0.05 with a positive +$0.11 or +0.24% Tuesday aftermarket
Sage Therapeutics (SAGE) closed down -$0.40 with a positive +$0.16 or +2.13% Friday aftermarket
The BOTTOM LINE: The cell and gene therapy sector enjoyed modest gains on Tuesday.
Although, more weakness could lie ahead with more wild swings like those seen over the past 2 months.
Moving forward through September, October and a few weeks of November, I believe the cell and gene therapy sector equities could be a bit rocky as Q3 LPS (loss-per-share) earnings releases step to bat.
- “Elevated prices for futures contracts tied to the Cboe Volatility Index VIX, better known as the VIX or “fear gauge,” suggest traders are bracing for such a risk.” <Matt Thompson, co-portfolio manager at Little Harbor Advisors.>
Keep a close eye on incoming economic data exposure as any sign of increased inflation is likely be a concern for investors.
As volatility is on-call in today’s sector
- I am STILL wondering if … sentiment is moribund.
- Keep overall exposure low and be ready to exit quickly.
- As I have joked, “uncle algo and his electronic trading dwarfs” come to roost” until they fly away!
Also, the closer we come to the U.S. presidential election; volatility could inject by the VIX (fear gauge) stimulating risk.
Welcome to my world of defining the “grey’ in our universe!
- Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
